Skip to main content
Top
Published in: Internal and Emergency Medicine 2/2019

01-03-2019 | IM - ORIGINAL

Red cell distribution width predicts mid-term prognosis in patients hospitalized with acute heart failure: the RDW in Acute Heart Failure (RE-AHF) study

Authors: Remo Melchio, Gianluca Rinaldi, Elisa Testa, Alessia Giraudo, Cristina Serraino, Christian Bracco, Laura Spadafora, Andrea Falcetta, Stefano Leccardi, Alberto Silvestri, Luigi Fenoglio

Published in: Internal and Emergency Medicine | Issue 2/2019

Login to get access

Abstract

The aim of the study was to evaluate the prognostic role of red cell distribution width (RDW) in a broad population of patients hospitalized for acute heart failure (AHF). In a retrospective cohort observational study, 451 consecutive patients discharged for AHF were categorized in patients with low RDW (≤ 14.8%) and high RDW (> 14.8%). The rates of death from all causes or of hospital readmission for worsening heart failure and death were determined after a median follow-up of 18 months. The overall population has a median age of 80 years (IQR 72–85), 235 patients (52%) were males. Patients with a higher RDW have more comorbidities and a higher Charlson Index. At follow-up, 200 patients (44%) had died and 247 (54%) had died or were readmitted for HF: in the cohort with low RDW, 70 patients (36.4%) had died, whereas in the cohort with high RDW, 165 patients (63.7%) had died: the unadjusted risk ratio of patients with high RDW was 2.03 (log-rank test: p < 0.0001). In a multivariate Cox regression model, the hazard ratio for death from any cause in the ‘high RDW’ cohort is 1.73 (95% confidence interval 1.2–2.48; p = 0.003); the RDW adds prognostic information beyond that provided by conventional predictors, including age; etiology of HF; anemia; hyponatremia; estimated glomerular filtration rate; NT-proBNP levels; Charlson comorbidity score, atrial fibrillation, functional status, therapy with renin–angiotensin–aldosterone system inhibitors, beta-blockers. RDW is a powerful marker of worse long-term outcomes in patients with AHF, and its prognostic value is maintained beyond that provided by other well-established risk factors or biomarkers.
Appendix
Available only for authorised users
Literature
3.
go back to reference Psotka MA, Teerlink JR (2013) Strategies to prevent postdischarge adverse events among hospitalized patients with heart failure. Heart Fail Clin 9:303–320CrossRefPubMed Psotka MA, Teerlink JR (2013) Strategies to prevent postdischarge adverse events among hospitalized patients with heart failure. Heart Fail Clin 9:303–320CrossRefPubMed
31.
go back to reference Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200mCrossRefPubMed Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200mCrossRefPubMed
Metadata
Title
Red cell distribution width predicts mid-term prognosis in patients hospitalized with acute heart failure: the RDW in Acute Heart Failure (RE-AHF) study
Authors
Remo Melchio
Gianluca Rinaldi
Elisa Testa
Alessia Giraudo
Cristina Serraino
Christian Bracco
Laura Spadafora
Andrea Falcetta
Stefano Leccardi
Alberto Silvestri
Luigi Fenoglio
Publication date
01-03-2019
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 2/2019
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-018-1958-z

Other articles of this Issue 2/2019

Internal and Emergency Medicine 2/2019 Go to the issue

CE - MEDICAL ILLUSTRATION

A sticking sensation in the throat!

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.